The I looked into channel digs into the retatrutide trial data to ask how much of the weight lost on the triple agonist may come from muscle.
Recap by typeshit. Full story at I looked into ....
The once-daily pill blocks the IL-23 receptor and helped people with moderate to severe ulcerative colitis respond more often than placebo, a new study reports.
Bikman welcomes a new result but argues the likely cause is tirzepatide bringing insulin down rather than the drug slowing aging itself. His view, not a study claim.
Marchione makes the case for pairing GLP-1s with drugs that target amylin, the hormone released after meals that signals fullness to the brain.
Regen says the placebo group saw a 9% drop, while people on retatrutide also lost 31 lb on average and saw systolic blood pressure fall 14 points.
Eric Fry sees upside on Wegovy pill demand, while Zacks expects 2026 revenue and EPS to fall. The FDA call on CagriSema is expected in Q4 2026.
A group of MPs is pressing for faster access to Mounjaro through the NHS, Sky News reports.
Loading…